Jason M. Melear

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome

Liver transplantation for Budd–Chiari syndrome: A European study on 248 patients from 51 centres

Vascular disorders of the liver # †

High incidence of recurrence and hematologic events following liver transplantation for Budd–Chiari syndrome

Inflammation and tumor progression: signaling pathways and targeted intervention

PROTAC targeted protein degraders: the past is prologue

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)

Platelet Density Distribution in Essential Thrombocythemia

Potential role for platelet apheresis for post‐liver transplant thrombocytosis complicating portal vein thrombosis

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1

MAGNIFY: Phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.